Hyderabad, India / Princeton, NJ, USA. December 24, 2018: Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA).
The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for the most recent twelve months ending in October 2018 according to IMS Health*.
Dr. Reddy’s Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size.
Aggrenox is a trademark of Boehringer Ingelheim.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Sign me up for the newsletter!
Notify me of follow-up comments by email.
Notify me of new posts by email.
IIT ROORKEE HOSTS A N KHOSLA ENDOWED LECTURE SERIES ON RIVER WATER DISPUTES BY PROF. KG RANGA RAJU IN THE MEMORY OF PADMA VIBHUSHAN DR. AJUDHIA NATH KHOSLA
Twitter celebrates 12th birthday of the ‘hashtag’
JAGUAR LAND ROVER INAUGURATES 3S RETAILER FACILITY IN PUNE
Expanding its footprint in Maharashtra, Travel Tours launches 3rd store in Mumbai
Dazzel Digital – One of the leading digital agencies in India
2014 The Global Indian New Network (TGINN)